ADMA ADMA BIOLOGICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ADMA BIOLOGICS INC reported revenue of $124M (up 2.0% from a year earlier), net income of $37.8M and diluted EPS of $0.16; over the last four quarters revenue was $512M and net income $169M; for the fiscal year ended December 2025 revenue was $510M, up 19.6% on the year before.

ADMA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $510M, gross profit $293M, operating income $191M, net income $147M (margin 28.8%), EPS $0.60
• Fiscal year ended Dec 2024: revenue $426M, gross profit $220M, operating income $139M, net income $198M (margin 46.4%), EPS $0.81
• Fiscal year ended Dec 2023: revenue $258M, gross profit $88.9M, operating income $21.6M, net income −$28.2M (margin -10.9%), EPS −$0.13
• Fiscal year ended Dec 2022: revenue $154M, gross profit $35.3M, operating income −$39.4M, net income −$65.9M (margin -42.8%), EPS −$0.33
• Fiscal year ended Dec 2021: revenue $80.9M, gross profit $1.17M, operating income −$58.4M, net income −$71.7M (margin -88.5%), EPS −$0.51

ADMA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $124M (up 2.0% year over year), net income $37.8M, EPS $0.16
• Quarter ended Mar 31, 2026: revenue $114M (down 0.3% year over year), net income $45.3M, EPS $0.19
• Quarter ended Dec 31, 2025 (from the annual report): revenue $139M (up 18.4% year over year), net income $49.4M, EPS $0.20
• Quarter ended Sep 30, 2025: revenue $134M (up 12.0% year over year), net income $36.4M, EPS $0.15
• Quarter ended Jun 30, 2025: revenue $122M (up 13.8% year over year), net income $34.2M, EPS $0.14
• Quarter ended Mar 31, 2025: revenue $115M (up 40.2% year over year), net income $26.9M, EPS $0.11
• Quarter ended Dec 31, 2024 (from the annual report): revenue $118M (up 59.1% year over year), net income $112M, EPS $0.45
• Quarter ended Sep 30, 2024: revenue $120M (up 78.1% year over year), net income $35.9M, EPS $0.15
• Quarter ended Jun 30, 2024: revenue $107M (up 78.3% year over year), net income $32.1M, EPS $0.13
• Quarter ended Mar 31, 2024: revenue $81.9M (up 43.9% year over year), net income $17.8M, EPS $0.08
• Quarter ended Dec 31, 2023 (from the annual report): revenue $73.9M (up 47.9% year over year), net income −$17.6M, EPS −$0.08
• Quarter ended Sep 30, 2023: revenue $67.3M (up 63.7% year over year), net income $2.57M, EPS $0.01
• Quarter ended Jun 30, 2023: revenue $60.1M (up 77.3% year over year), net income −$6.37M, EPS −$0.03
• Quarter ended Mar 31, 2023: revenue $56.9M (up 95.6% year over year), net income −$6.79M, EPS −$0.03
• Quarter ended Dec 31, 2022 (from the annual report): revenue $50.0M (up 89.4% year over year), net income −$12.2M, EPS −$0.05
• Quarter ended Sep 30, 2022: revenue $41.1M (up 98.7% year over year), net income −$14.9M, EPS −$0.08
• Quarter ended Jun 30, 2022: revenue $33.9M (up 90.2% year over year), net income −$13.8M, EPS −$0.07
• Quarter ended Mar 31, 2022: revenue $29.1M (up 81.3% year over year), net income −$25.0M, EPS −$0.13
• Quarter ended Dec 31, 2021 (from the annual report): revenue $26.4M, net income −$16.7M, EPS −$0.07
• Quarter ended Sep 30, 2021: revenue $20.7M, net income −$17.7M, EPS −$0.13

ADMA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $50.4M, share buybacks $31.9M
• Fiscal year ended Dec 2024: operating cash flow $119M, share buybacks $0
• Fiscal year ended Dec 2023: operating cash flow $8.80M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$59.5M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$112M, share buybacks n/a

ADMA balance sheet

• Jun 30, 2026: cash $136M, total assets $684M, total liabilities $276M, shareholders' equity $408M, long-term debt $193M
• Mar 31, 2026: cash $138M, total assets $665M, total liabilities $275M, shareholders' equity $390M, long-term debt $194M
• Dec 31, 2025: cash $87.6M, total assets $624M, total liabilities $147M, shareholders' equity $477M, long-term debt $69.3M
• Sep 30, 2025: cash $61.4M, total assets $569M, total liabilities $138M, shareholders' equity $431M, long-term debt $70.1M
• Jun 30, 2025: cash $90.3M, total assets $558M, total liabilities $160M, shareholders' equity $398M
• Mar 31, 2025: cash $71.6M, total assets $511M, total liabilities $137M, shareholders' equity $373M
• Dec 31, 2024: cash $103M, total assets $489M, total liabilities $140M, shareholders' equity $349M, long-term debt $72.3M
• Sep 30, 2024: cash $86.7M, total assets $391M, total liabilities $159M, shareholders' equity $232M

What is ADMA's revenue?

ADMA BIOLOGICS INC reported $512M of revenue over its last four quarters, through June 30, 2026.

Is ADMA profitable?

Yes. ADMA BIOLOGICS INC earned $169M over the last four quarters.

What is ADMA's EPS?

Diluted earnings per share over the last four quarters were $0.70; $0.16 in the latest quarter.

ADMA ownership and insider trades · All stocks